(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 July 2010 (29.07.2010)

PCT

(10) International Publication Number
WO 2010/085213 A1

(51) International Patent Classification:
C12N 15/11 (2006.01) *C12Q 1/68* (2006.01)

(21) International Application Number:
PCT/SG2010/000020

(22) International Filing Date:
22 January 2010 (22.01.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/147,030 23 January 2009 (23.01.2009) US

(71) Applicants *(for all designated States except US)*: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). **KAROLINSKA INSTITUTET** [SE/SE]; Nobels Vag 12B, S-171 77 Stockholm (SE). **CLINICAL RESEARCH INSTITUTE HELSINKI UNIVERSITY CENTRAL HOSPITAL** [FI/FI]; Haartmaninkatu 8, FI-00290 Helsinki (FI).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LIU, Jianjun** [CN/SG]; Genome Institute Of Singapore, Biomedical Science Institute, 60 Biopolis Street, Genome #02-01, Singapore 138672 (SG). **LIU, Tak-Bun, Edison** [CN/SG]; Genome Institute Of Singapore, Biomedical Sciences Institutes, 60 Biopolis Street, Genome #02-01, Singapore 138672 (SG). **NEVANLINNA, Heli** [FI/FI]; Department Of Obstetrics And Gynecology, Helsinki University Central Hospital, Biomedicum Helsinki 4th Floor, P.O. Box 700, FI-00029 Helsinki (FI). **HALL, Per** [SE/SE]; Department Medical Epidemiology And Biostatistics, Nobelsvag 12 Karolinska Institutet, S-171 77 Stockholm (SE).

(74) Agent: **ATMD BIRD & BIRD LLP**; 2 Shenton Way, #18-01, SGX Centre 1, Singapore 068804 (SG).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: SINGLE NUCLEOTIDE POLYMORPHISM WITHIN AN INTRONIC p53 BINDING MOTIF OF THE PRKAG2 GENE

Figure 1



(57) Abstract: The present invention relates to single nucleotide polymorphism (SNP). In particular, it relates to a SNP within an intronic p53 binding motif of the PRKAG2. Nucleic acid molecules and methods for aiding assessment of a patient's risk of developing cancer by determining the patient's genotype for a p53 binding motif within the PRKAG2 gene are included in the present invention.

WO 2010/085213 A1